Annex

QUESTIONNAIRE FOR THE TESTING OF THE GUIDANCE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

GENERAL INFORMATION ABOUT THE TESTING							
Q1. These results are being submitted on behalf of a:	☐ Party. Please specify: Banadir University, Mogadishu, Somalia						
	☐ Other Government. Please specify: <somali government=""></somali>						
	Organization: Please specify: <whitelink consultancies,="" somalia=""></whitelink>						
Q2. When was the testing of the Guidance conducted?	Please enter date: 19, November, 2011						
Q3. Type of event where the testing of the Guidance was conducted?	\boxtimes	Group event (e.g., workshop, training course, meeting). Please provide the title of the event and name of organizer: Workshop, facilitated Whitelink Consultancies Group. >					
		Type of meeting:					
		Online					
		☐ Individual exercise. Please provide your name, occupation and affiliation: <dr. ali="" dds="" khalid="" omar=""></dr.>					
		Other: Ple	ease specify: <	Ahmed Mol	named Iman Sei	nior Adviser >	•
Q4. Which sections of the Guidance were tested?	\boxtimes	☐ Part I: The Roadmap for Risk assessment of LMOs					
	Part II: Specific types of LMOs or Traits:						
	☐ Risk assessment of LMOs with stacked genes or traits						
	Risk assessment of LM crops with tolerance to abiotic stress						
	☐ Risk assessment of LM mosquitoes						
	(OVERALL	EVALUATIO	ON			
			Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you as	ttribute	to each of t	the questions	in the left col	<u>lumn.</u>		
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?							
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a scientifically sound and case-by-case manner?				\boxtimes			
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?				\boxtimes			

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.					
Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>			
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments: <type here=""></type>			
Q10. Is the Roadmap organized in a logic and structured manner?	☐ Yes ⊠ No	Comments: lack of resourses>			
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	☐ Yes ⊠ No	Comments: <type here=""></type>			
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	☐ Yes ⊠ No	Comments: <not applicable="" yet=""></not>			
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	☐ Yes ☑ No	Comments: <not applicable="" yet=""></not>			
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ☑ No	Comments: <type here=""></type>			
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: it is exellent presentation related this assue>			

PART II: SPECIFIC TYPES OF LIVING MODIFIED ORGANISMS OR TRAITS

Risk assessment of living modified organisms with stacked genes or traits

ğ	0	Ü				
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q16. Does this section provide useful guidance when conducting risk assessments of LMOs with stacked genes or traits in accordance with the Protocol?	⊠ Yes □ No	Comments: < it is most usefull on the guidance and introduction.>				
Q17. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LMOs with stacked genes of traits?	☐ Yes ☐ No	Comments: <it additional="" building="" capcity="" could="" for="" good="" if="" is="" new="" or="" other="" parties.="" planning="" the="" training="" you=""></it>				
Q18. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q19. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	☐ Yes ⊠ No	Comments: <type here=""></type>				
Q20. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ☑ No	Comments: <it fine="" is=""></it>				
Risk assessment of living modified crops with tolerance to abiotic stress						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q21. Does this section provide useful guidance when conducting risk assessments of LM crops with tolerance to abiotic stress(es) in accordance with the Protocol?	⊠ Yes □ No	Comments: <it abiotic="" be="" clear="" must="" stress=""></it>				
Q22. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM crops with tolerance to abiotic stress(es)?	☐ Yes ⊠ No	Comments: <for abiotic="" experience="" for="" lack="" of="" stresses=""></for>				
Q23. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <we after="" get="" it.="" more="" read="" usefull=""></we>				
Q24. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	☐ Yes ☑ No	Comments: <type here=""></type>				
Q25. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ☑ No	Comments: <>				

Risk assessment of living modified mosquitoes							
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.							
Q26. Does this section provide useful guidance when conducting risk assessments of LM mosquitoes in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>					
Q27. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM mosquitoes?	⊠ Yes □ No	Comments: <africa continental="" experience="" for="" has="" limited="" lm="" masquitoes="" of="" risk=""></africa>					
Q28. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>					
Q29. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>					
Q30. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ⊠ No	Comments: <type here=""></type>					

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.

Q31. < there no same capacity for the developed countries and LDCs. we suggest to will provide a trainig to upgrating the Focal Point came from LDCs >
